By Julie Zeveloff

Law360, New York (November 06, 2008, 12:00 AM ET) -- A federal judge has dismissed claims of willful infringement from four separate actions brought by Celgene Corp. and Novartis Pharmaceuticals Corp. to stop several rival pharmaceutical companies from marketing and selling generic versions of Focalin XR, an attention deficit hyperactivity disorder medication.

U.S. District Judge Freda L. Wolfson of the U.S. District Court for the District of New Jersey signed off on the order Wednesday, absolving Teva Pharmaceuticals USA Inc., Actavis South Atlantic LLC, IntelliPharmaCeutics Corp. and Barr Pharmaceuticals Inc., as well as their subsidiaries, from...